| |
|
 |
 |
|
For press inquiries, please contact:
Media Contact:
Mike Beyer
Sam Brown Inc.
312-961-2502
beyer@sambrown.com
|
|
|
Archives 2009
All 2009 Releases
 |
EnteroMedics Receives Notice of NASDAQ Listing Deficiencies
Nov 19, 2009
|
12.6 KB |
|
| |
ST. PAUL, Minn., Nov 19, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, announced today that on November 13, 2009 it received two
Nasdaq Staff Deficiency Letters indicating that, for 30 consecutiv...
|
|
EnteroMedics Announces Preliminary Results from Detailed Review of EMPOWER Study
Nov 12, 2009
|
16.0 KB |
|
| |
ST. PAUL, Minn., Nov 12, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, today announced preliminary findings from its ongoing
detailed review of its EMPOWER(TM) study, a randomized, double-blind, ...
|
|
EnteroMedics Announces Reduction in Workforce
Oct 27, 2009
|
11.6 KB |
|
| |
ST. PAUL, Minn., Oct 27, 2009 (BUSINESS WIRE) -- EnteroMedics Inc., (NASDAQ: ETRM) today announced that it has
implemented a plan to reduce its workforce and operating costs in order
to preserve capital and streamline its operations following the
announcement of top-line results from its pivotal EMPOWER study on
Octo...
|
|
EnteroMedics Announces Third Quarter 2009 Financial Results
Oct 23, 2009
|
18.0 KB |
|
| |
ST. PAUL, Minn., Oct 23, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, today reported financial results for the three and nine
months ended September 30, 2009.
For the three months ended Septemb...
|
|
EnteroMedics Announces $4.9 Million Financing
Oct 2, 2009
|
12.8 KB |
|
| |
ST. PAUL, Minn., Oct 02, 2009 (BUSINESS WIRE) -- EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices
using neuroblocking technology to treat obesity, its associated
co-morbidities, and other gastrointestinal disorders, today announced
that it has entered into a definitive agreement with an institutional
...
|
|
EnteroMedics Announces Preliminary Results of its EMPOWER(TM) Study
Oct 2, 2009
|
12.4 KB |
|
| |
ST. PAUL, Minn., Oct 02, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, today announced preliminary results from its EMPOWER(TM) Study.
Based on an initial analysis, the study did not meet its pri...
|
|
EnteroMedics Appoints Dan Cohen as Senior Vice President of Government Relations and Health Policy
Sep 24, 2009
|
12.7 KB |
|
| |
ST. PAUL, Minn., Sep 24, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, today announced that Dan Cohen has joined the Company as
Senior Vice President for Government Relations and Health Policy. M...
|
|
EnteroMedics to Present at the 29th Annual Canaccord Adams Global Growth Conference
Aug 4, 2009
|
11.8 KB |
|
| |
ST. PAUL, Minn., Aug 04, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM) announced today that Mark B. Knudson,
Ph.D., Chief Executive Officer, is scheduled to present at the Canaccord
Adams' 29th Annual Global Growth Conference in Boston, MA on Tuesday,
August 11th at 9:00 am ET. Dr. Knudson will provide an overview...
|
|
EnteroMedics Reports Second Quarter 2009 Financial Results
Jul 23, 2009
|
16.3 KB |
|
| |
ST. PAUL, Minn., Jul 23, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, today announced financial results for the three and six
months ended June 30, 2009.
For the three months ended June 30, 200...
|
|
EnteroMedics is Added to the Russell 3000(R) Index
Jun 30, 2009
|
12.1 KB |
|
| |
ST. PAUL, Minn., Jun 30, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, announced today that it was added to the Russell 3000(R) Index
on June 26, 2009.
Annual reconstitution of Russell's U.S. in...
|
|
Nicholas Teti to Consult as Special Advisor to the Chief Executive Officer, Commercialization and Business Development
Jun 2, 2009
|
13.1 KB |
|
| |
ST. PAUL, Minn., Jun 02, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, announced today that Nicholas L. Teti, Jr., a member of
EnteroMedics' Board of Directors since 2007 will be consulting as
...
|
|
EnteroMedics to Present at the Canaccord Adams Annual Diabetes and Obesity Conference
May 4, 2009
|
11.8 KB |
|
| |
ST. PAUL, Minn., May 04, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, announced today that Mark B. Knudson, Ph.D., Chief Executive
Officer, is scheduled to present at the Canaccord Adams annual ...
|
|
EnteroMedics Reports First Quarter 2009 Financial Results
Apr 23, 2009
|
14.5 KB |
|
| |
ST. PAUL, Minn., Apr 23, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, announced today its financial results for the first quarter
ended March 31, 2009.
The Company reported a net loss of $6.7 m...
|
|
EnteroMedics Receives CE Mark Certification for the Maestro System for Obesity Therapy
Mar 9, 2009
|
13.0 KB |
|
| |
ST. PAUL, Minn., Mar 09, 2009 (BUSINESS WIRE) -- EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices
using neuroblocking technology to treat obesity, its associated
co-morbidities, and other gastrointestinal disorders, announced today
that it has received CE Mark approval of VBLOC(TM) Therapy delivered via
...
|
|
EnteroMedics Announces $15.89 Million Private Placement
Feb 20, 2009
|
13.0 KB |
|
| |
ST. PAUL, Minn., Feb 20, 2009 (BUSINESS WIRE) -- EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices
using neuroblocking technology to treat obesity, its associated
co-morbidities, and other gastrointestinal disorders, today announced
that on February 19, 2009, it entered into binding securities purchase
...
|
|
EnteroMedics Reports 2008 Year-End Financial Results
Jan 29, 2009
|
15.5 KB |
|
| |
ST. PAUL, Minn., Jan 29, 2009 (BUSINESS WIRE) -- EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices
using neuroblocking technology to treat obesity, its associated
co-morbidities, and other gastrointestinal disorders, today announced
financial results for the three months and full year ended December 31,
...
|
|
EnteroMedics Elects Jon T. Tremmel to Board of Directors
Jan 28, 2009
|
12.4 KB |
|
| |
ST. PAUL, Minn., Jan 28, 2009 (BUSINESS WIRE) -- EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices
using neuroblocking technology to treat obesity, its associated
co-morbidities, and other gastrointestinal disorders, today announced
the election of Jon T. Tremmel to the Company's Board of Directors. Mr.
...
|
|
EnteroMedics Announces Eighteen-Month Excess Weight Loss Results from its VBLOC-RF2 Feasibility Study
Jan 12, 2009
|
13.3 KB |
|
| |
ST. PAUL, Minn., Jan 12, 2009 (BUSINESS WIRE) -- EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices
using neuroblocking technology to treat obesity, its associated
co-morbidities, and other gastrointestinal disorders, today announced
interim clinical results from the VBLOC-RF2 feasibility study of the
...
|
|
EnteroMedics to Present at the 27th Annual JP Morgan Healthcare Conference
Jan 5, 2009
|
12.9 KB |
|
| |
ST. PAUL, Minn., Jan 05, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM) announced today that Mark B. Knudson,
Ph.D., Chief Executive Officer, is scheduled to present at the 27th
Annual JP Morgan Healthcare Conference, Wednesday January 14, 2009 at
8:00 AM PT. Dr. Knudson will provide an overview of the Company and ...
|
| Showing 1-19 of 19 |
Page: 1 |
|
|
= add release to Briefcase
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
